Emmes, a global, full-service Clinical Research Organization (CRO), has acquired Clinical Edge. Clinical Edge trains and certifies visual function examiners at investigator sites conducting Phase I to IV ophthalmic clinical trials.
 
The combination of Optym, Emmes’ ophthalmology certification unit, and Clinical Edge expands its ophthalmic certification and training services.
 
Emmes Chief Executive Officer Dr. Christine Dingivan, said, “This acquisition makes us a powerhouse in the ophthalmology training and certification area, a critical part of determining the safety and efficacy of new treatments for eye disease. Our fifth acquisition in less than two years, this is another positive step in our growth and globalization effort. It also reflects our commitment to investing in public health and alleviating the high burden of disease areas like ophthalmology.”
 
OptymEdge ensures the standardization of visual function requirements for ophthalmic clinical trials across all phases of clinical development. This includes certifying and training of clinical trial center staff and maintaining a database listing their current certification status. OptymEdge has a combined base of 36 ophthalmic certifiers, most of whom are doctors of optometry and medical doctors.
 
Lisa Laskowski, managing director of Clinical Edge, added, “We are thrilled to be joining a first-rate organization like Emmes, which mirrors our principles and aspirations. This partnership will strengthen and optimize our client services.”